Drug Information

Drug (ID: DG01869) and It's Reported Resistant Information

• Name: SF1126
• Synonyms: SF1126
• Indication:
  In total 3 Indication(s)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Phase 1; [1]
  Head and neck cancer [ICD-11: 2D42]; Phase 2; [1]
  Hepatocellular carcinoma [ICD-11: 2C12]; Phase 2; [1]
• Target: PI3-kinase gamma (PIK3CG); PK3CG_HUMAN; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase Hras (HRAS) [1]

• Molecule Alteration: Missense mutation; p.G12V (c.35G>T)
• Sensitive Disease: Brain glioma [ICD-11: 2A00.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: U87MG glioma cells; Brain; Homo sapiens (Human); CVCL_0022
• In Vivo Model: Athymic female (CD-1 Nu/Nu) mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Kinase-Glo luminescent assay

References

• Ref 1: Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma modelCancer Cell Int. 2014 Nov 12;14(1):105. doi: 10.1186/s12935-014-0105-9. eCollection 2014.